NCT05563467View on ClinicalTrials.gov

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

Pembrolizumab 25 MG/ML [Keytruda]

The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.

Trial Locations (4)

44-102

RECRUITING

Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice

Unknown

RECRUITING

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie, Krakow

RECRUITING

Uniwersytecki Szpital Kliniczny W Poznaniu, Poznan

RECRUITING

Medical University Of Warsaw, Warsaw

All Listed Sponsors
collaborator

Biostat Sp. z o.o.

UNKNOWN

lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER